WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19 by Jonathan Barratt, Bart Maes, Rubeen Israni, Xuelian Wei, Vladimir Tesar, Gerald Appel, Yusuke Suzuki, Celia Lin, Richard Lafayette

Get full text

WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY by Jonathan Barratt, Bart Maes, Celia Lin, Xuelian Wei, Sean Barbour, Richard Phoon, Sung Gyun Kim, Vladimir Tesar, Jürgen Floege, Vivekanand Jha, Richard Lafayette

Get full text

WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY by Jonathan Barratt, Bart Maes, Rubeen Israni, Xuelian Wei, Jürgen Floege, Vivekanand Jha, Vladimir Tesar, Hong Zhang, Sean Barbour, Hitoshi Suzuki, Hernan Trimarchi, Celia Lin, Richard Lafayette

Get full text

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN by Vivekanand Jha, Richard Lafayette, Sean Barbour, Robert Brenner, Kerry Cooper, Xuelian Wei, Necmi Eren, Jürgen Floege, Sung Gyun Kim, Bart Maes, Richard Phoon, Harmeet Singh, Vladimír Tesař, Jonathan Barratt

Get full text